SU 5205
- CAS NO.:3476-86-6
- Empirical Formula: C15H10FNO
- Molecular Weight: 239.24
- MDL number: MFCD00435356
- SAFETY DATA SHEET (SDS)
- Update Date: 2026-07-27 17:00:41
What is SU 5205?
Biological Activity
SU5205 is an inhibitor of VEGF receptor 2 (VEGFR2/FLK-1) with IC50 of 9.6 μM.
in vitro
SU5205 inhibits ligand-induced endothelial mitogenesis for VEGF with an IC 50 of 5.1 μM.
Properties of SU 5205
| Melting point: | 194-196 °C |
| Boiling point: | 435.3±45.0 °C(Predicted) |
| Density | 1.306±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMF: 50 mg/ml; DMSO: 50 mg/ml; DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml; Ethanol: 5 mg/ml |
| form | A crystalline solid |
| pka | 12.69±0.20(Predicted) |
| color | White to yellow |
Safety information for SU 5205
Computed Descriptors for SU 5205
New Products
2-(2-Chlorophenyl)glycine Propiolic Acid 1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene (±)-amino(2-fluorophenyl)acetic acid trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 1-Pentadecanol 4-(4-Αminophenyl)-3-Morpholinone 3-Morpholino-1-(4-(2-oxopiperidin-1-yl) phenyl)-5,6-dihyropyridin-2-(1H)-one 1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one N-cyanoacetylurethane 1H-IndazoleRelated products of tetrahydrofuran








You may like
-
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
471-25-0 Propiolic Acid 98+View Details
471-25-0 -
84145-28-8 98+View Details
84145-28-8 -
trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 98+View Details
63909-29-5 -
2-(2-Chlorophenyl)glycine 88744-36-9 98+View Details
88744-36-9 -
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
629-76-5 98+View Details
629-76-5 -
1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene 98+View Details
39816-35-8
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
